Keywords
Secukinumab,G1,IgG,IgG1,igG1-K
anti-TNF,monoclonal antibody,TNF,tumour necrosis factor,tumor,cosentyx,human recombinant,antibody,b cell receptor,Humira,rheumatoid arthritis,psoriasis,psoriatic arthritis,ankylosing spondylitis,interleukin-17a,molecule,macromolecule,protein,Ab,immunoglobulin,Ig,immune system,adaptive immune system,immune,system,immune,immunoglobin,immunological,antigen-binding,antitoxin,agent,drug,antigen,competitor,ADC,binding agent,small molecule,antibody tag,antibody label,adc tag,adc therapy,mab,monoclonal,nanobody,fabs,neutralizing,polyclonal,single domain,antigen-binding site,immunoglobulin G,igG,immunoglobulin E,IgE,immunoglobulin D,IgD,immunoglobulin A,IgA,immunoglobulin M,IgM,antibodies,rounded,heavy chain,light chain,y-shaped,disulfide bond,variable region,constant region,agglutinin,precipitin,seroglobulin,gamma globulin,biopharmaceutical,targeted delivery,drug release,cytotoxic action,therapeutic,cancer,treatment,targeted therapy,chemotherapy,immunology,oncology,biochemistry,molecular biology,pharmacology,biotechnology,edit,editable,popular biotechnology icons,popular immunology icons,Rectangular,Binding sites,Antigen binding sites,proj-content-refinement-24q2,proj-content-refinement-antibodies-24q2,igg1,Secukinumab,cosentyx